Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0000000000000262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis.
Acta Neuropathol Commun
December 2024
Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
Evidence that myelin repair is crucial for functional recovery in multiple sclerosis (MS) led to the identification of bexarotene (BXT). This clinically promising remyelinating agent activates multiple nuclear hormone receptor subtypes implicated in myelin repair. However, BXT produces unacceptable hyperlipidemia.
View Article and Find Full Text PDFReversible cerebral vasoconstriction syndrome following carotid artery revascularization: About three case reports and review of literature.
J Med Vasc
December 2024
Service de neurologie, boulevard Professeur-Jacques-Monod, 44800 Saint-Herblain, France.
Complication after carotid artery revascularization is mainly represented by stroke. Reversible cerebral vasoconstriction syndrome triggering by carotid artery revascularization is exceptional but it is an unrecognized aetiology of stroke. It could be associated with brain edema and henceforth, a posterior reversible encephalopathy syndrome can be confused with post-carotid artery revascularization cerebral hyperperfusion syndrome.
View Article and Find Full Text PDF[Post-Stroke Epilepsy and Vascular Dementia].
No Shinkei Geka
November 2024
Department of Neurology, National Cerebral and Cardiovascular Center Hospital.
Article Synopsis
- - Post-stroke complications like epilepsy and cognitive impairment are on the rise due to an aging population, with post-stroke epilepsy making up about half of epilepsy cases in older adults, highlighting the need for effective seizure management.
- - Research is advancing in areas such as diagnostic techniques and preventative strategies for post-stroke epilepsy while also emphasizing the importance of controlling vascular risk factors to potentially prevent conditions like vascular dementia and Alzheimer's.
- - The review provides essential clinical information, including diagnostic criteria, classification, risk factors, measurements, and treatment options for managing complications that arise post-stroke.
Clinical and Radiological Characteristics of Classical and Variant Type of Posterior Reversible Encephalopathy Syndrome on Prognosis Following Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Center Experience.
Exp Clin Transplant
October 2024
From the Department of Pediatric Hematology-Oncology and Bone Marrow Transplantation, Acibadem Adana Hospital, Adana, Turkey.
Objectives: Hematopoietic stem cell transplant is increasingly being used as a curative therapeutic option for patients with hematologic malignancies and nonmalignant diseases. Here, we aimed to determine the frequency and features of typical and atypical central variants of posterior reversible encephalopathy syndrome in children who had undergone an allogeneic hematopoietic stem cell transplant procedure for any indication at a single center.
Materials And Methods: We retrospectively analyzed 101 pediatric patients between aged 6 months and 18 years who had undergone hematopoietic stem cell transplant for any indication between 2010 and 2023.
Reversible posterior leukoencephalopathy syndrome (RPLS) in a patient with chronic lymphocytic leukemia (CLL) treated with Acalabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor: a case report.
Acta Neurol Belg
November 2024
Department of Neurology, AZ Sint-Jan Bruges Hospital, Bruges , Belgium.
RPLS is a rare neuroradiologic syndrome characterized by headache, visual disturbances, focal deficits and confusion. There are several underlying mechanisms causing RPLS, including arterial hypertension and renal failure, but also treatments with immunosuppressive therapy, chemotherapy or targeted therapy (such as small molecule inhibitors). Acalabrutinib is a novel second-generation BTK inhibitor, frequently used as treatment for B-cell malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!